Nachrichten zur CROSSJECT S.A. Aktie

Dijon, France, December 19, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company preparing to commercialize…

Dijon, FRANCE, December 11, 2024 – 8 a.m. (CET) – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing…

Dijon, France, December 09, 2024, 07:30 CET – Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning…

Dijon, France, November 13, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning needle-free ZENEO®…

Enables French retail investors to buy securities under preferential tax conditions Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265;…

Dijon, France Sept 26, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing medicines for emergency situations…

Dijon, France, September 23, 2024 18:00 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company developing the award-winning…

Dijon, France, July 18, 2024, 07:30 CET -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases…

Dijon, France 26 June, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharma company in advanced phases of development…

Gross fundraising of approximately €8 million or 100% of the planned rights offering as proposed and announced on 30 April…

 …

Dijon, France April 25, 2024 -- Crossject (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company developing products for emergency situations…